Abstract
ALTHOUGH sympathomimetic amines with vasoconstrictor (alpha-adrenergic) activity are commonly given to elevate the systemic blood pressure in hypotensive states, their use has been questioned on the basis that vasoconstriction may result in reduced blood flow to visceral organs.1 Most clinically useful sympathomimetic amines, however, also possess potentially beneficial beta-adrenergic activity, which results in increased myocardial contractility.2 Attempts to achieve myocardial stimulation without vasoconstriction have centered on the use of sympathomimetic amines with predominant beta-adrenergic activity (isoproterenol,3 or epinephrine4) or on the conjoint use of alpha-adrenergic blocking agents with amines possessing both alpha and beta activity (norepinephrine5 or metaraminol). Although . . .
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
